The future of medicine is federated

Why Genomic Data Federation Is the Key to Unlocking Precision Medicine

Genomic data federation is the practice of enabling researchers to query and analyze genomic datasets across multiple institutions, countries, or systems — without ever moving the underlying data.

Here is a quick breakdown of what it means and why it matters:

The Crisis of Unused Data

Today, an estimated 97% of hospital data goes unused. It sits locked in silos — spread across institutions, provinces, cloud platforms, and software systems — out of reach for the researchers who need it most. This is not just a technical failure; it is a missed opportunity for patients waiting for life-saving treatments. In the context of rare diseases, where a single hospital might only see one patient with a specific mutation every decade, the inability to connect that data with other cases globally is a significant barrier to discovery.

The problem is not a lack of data. We have more genomic data than ever before, thanks to the plummeting costs of sequencing. The problem is access. Traditional approaches require moving sensitive data to a central repository before any analysis can begin. That model is slow, expensive, and increasingly incompatible with regulations like GDPR and HIPAA. It creates bottlenecks that delay discoveries in areas like rare disease, oncology, and pandemic response — where speed and scale can mean lives saved.

The “Data Gravity” Problem

As datasets grow into the petabyte scale, they develop “data gravity.” The cost and time required to move these massive files across the internet become prohibitive. Egress fees from cloud providers can reach hundreds of thousands of dollars, and the physical time required to transfer data can take weeks. Federation flips this model on its head. Instead of bringing data to the code, you bring the code to the data.

This shift is not theoretical. Over 1.6 million SARS-CoV-2 genomes have already been processed and shared through a global federated network for pandemic surveillance — without centralizing a single genome. Federated networks now span Europe, Canada, and beyond, connecting institutions that could never have shared data under legacy models.

I am Maria Chatzou Dunford, CEO and Co-founder of Lifebit, and I have spent over 15 years building the computational infrastructure that makes genomic data federation possible — from developing workflow tools used globally in genomic analysis to leading Lifebit’s work powering secure, federated research environments for public sector and pharmaceutical partners worldwide. In this guide, I will walk you through exactly how to implement genomic data federation in practice, what governance and technical standards you need, and where this field is heading next.

Genomic data federation terms at a glance:

• what is a federated data platform
• federated data exchange platform
• Centralized data access

Why Centralized Databases are Failing Modern Precision Medicine

For decades, the “gold standard” for big data was centralization. If you wanted to find the genetic drivers of a rare disease, you gathered all the samples into one giant bucket. But in the era of Next-Generation Sequencing (NGS), this bucket has become a liability. The centralized model assumes that data is a static resource that can be easily moved, but genomic data is dynamic, sensitive, and legally protected.

The Volume and Velocity Challenge

The sheer volume of data is the first hurdle. Genomic files are massive; moving them across borders or even between cloud providers incurs significant “egress” costs and takes days, if not weeks. As we move toward population-scale sequencing—where countries sequence hundreds of thousands of citizens—the centralized model breaks down entirely. You cannot move a petabyte of data every time a researcher wants to run a new analysis.

The Regulatory Landscape

More importantly, data movement often breaks the law. With the rise of GDPR in Europe and similar sovereignty laws in Canada and Singapore, genomic data is increasingly classified as “special category data.” These regulations often mandate that patient data stays within national or jurisdictional boundaries to protect privacy. In many cases, the legal risk of moving data outweighs the potential scientific benefit, leading to “data hoarding” where institutions keep data locked away to avoid compliance headaches.

The Diversity Gap

When we force data into centralized repositories, we also create “data silos.” Research institutions are often hesitant to relinquish control of their datasets due to security concerns or a lack of clear attribution. This results in a lack of diversity; if we only analyze data from a few centralized Western hubs, our precision medicine tools won’t work for the rest of the world. This is a critical issue for health equity. As highlighted in Democratizing clinical-genomic data: How federated platforms can promote benefits sharing, federation is the only way to bridge these gaps while respecting local governance. By adopting a Federated Architecture in Genomics, we can finally stop moving the data and start moving the insights. This allows for a more inclusive research ecosystem where data from diverse populations can be analyzed in situ, ensuring that the benefits of genomic medicine are accessible to all.

How to Implement Genomic data federation in 5 Strategic Steps

Implementing Genomic data federation isn’t just about plugging in a new piece of software; it’s about building a “bridge” between different data owners. We look at it as creating an “Internet of Genomics” where every database speaks the same language. This requires a combination of technical standards, secure infrastructure, and robust governance.

To get started, you need to align your infrastructure with global standards. The Global Alliance for Genomics and Health (GA4GH) has developed the blueprints for this. One of the most critical tools in our arsenal is the Data Connect Standard, which acts as a universal translator. It allows us to describe data models via simple tables and query them using standard SQL, regardless of whether the data lives in a CSV file, a cloud bucket, or a relational database. For a deeper dive, check out our Federated Data Sharing Complete Guide.

Step 1: Standardize with Genomic data federation Protocols

The first step in any federation project is making the data “discoverable.” You can’t analyze what you can’t find. This is where the Beacon Project Website and its Beacon v2 protocol come into play. Think of Beacon as a “lingua franca” for genomics. In its simplest form, a researcher asks: “Do you have a sample with this specific genetic mutation?” The federated node replies with a simple “Yes” or “No.”

Beacon v2 goes much further, allowing for complex queries about phenotypes and clinical data. By standardizing your metadata—the “data about the data”—you ensure that a researcher in London can query a dataset in Canada and get a meaningful result without needing to understand the local database’s unique quirks. This interoperability is the bedrock of a Federated Research Environment Complete Guide.

Step 2: Deploy Federated Learning for Secure AI Training

Once your data is discoverable and standardized, you can move from simple queries to advanced AI. This is where Federated Learning (FL) changes the game. In traditional AI training, you’d pull all the data into one server to train a model. In a federated setup, you keep the data exactly where it is. We send the AI model to the data. Each institution trains the model locally on its own private dataset. Then, instead of sharing the raw data, they share only the “model updates” (the mathematical adjustments the AI learned). These updates are aggregated into a global model that is smarter than any single local version could ever be. You can see how this works in practice in our Federated Learning Applications guide.

Step 3: Implement Workflow Execution Standards (WES)

To ensure that analysis is reproducible across different sites, you must use standardized workflow execution. The GA4GH Workflow Execution Service (WES) API allows researchers to run the same analysis pipeline (e.g., a Nextflow or WDL script) across multiple federated nodes. This ensures that the results are comparable, regardless of whether the computation happened on AWS in the US or an on-premise server in Germany. This step eliminates the “it works on my machine” problem that plagues bioinformatics.

Step 4: Establish Federated Identity and Access Management (IAM)

Security is paramount. You need a system that allows researchers to use a single identity (e.g., their university login) to access multiple federated datasets. Using standards like GA4GH Passports, you can encode a researcher’s permissions and “visas” into a digital token. This token travels with their query, proving to each local data custodian that the researcher is authorized to perform the requested analysis. This automates the trust relationship between institutions.

Step 5: Enable Federated Data Discovery and Analytics

The final step is providing a unified interface where researchers can perform cross-cohort analysis. This involves using the GA4GH Discovery APIs to search across all federated nodes simultaneously. A researcher can build a virtual cohort of 10,000 patients by pulling 2,000 from five different countries, running a single analysis that spans the entire network without the data ever leaving its original jurisdiction.

Overcoming the Privacy-Utility Tradeoff with Federated Governance

The biggest fear in data sharing is the “privacy-utility tradeoff.” The more useful the data is for science, the more identifiable it potentially becomes for the patient. Genomic data federation solves this by shifting from “all-or-nothing” access to a structured, governed approach that prioritizes security without stifling innovation.

Effective Federated Data Governance relies on Data Access Committees (DACs). Instead of one central body deciding who gets in, each data custodian maintains their own DAC. They decide which researchers are “trusted” and what level of data they can see. This preserves the sovereignty of the data owner while enabling collaboration.

The “Five Safes” Framework in Federation

To manage risk, many federated networks adopt the “Five Safes” framework:

1. Safe Projects: Is the research for the public good?
2. Safe People: Is the researcher verified and affiliated with a reputable institution?
3. Safe Settings: Does the federated environment prevent data egress?
4. Safe Data: Is the data appropriately de-identified for the requested task?
5. Safe Outputs: Are the results checked to ensure no individual can be re-identified?

Managing Access Levels in Genomic data federation

Not all research requires the same level of detail. To keep things secure, we use “tiered access” models. This was famously pioneered by the International Cancer Genome Consortium (ICGC) and is now a standard practice.

1. Open Access: Non-identifiable, high-level summary data available to anyone. This is useful for initial feasibility studies.
2. Registered Access: Available to bona fide researchers who have agreed to a code of conduct. This often includes access to more detailed metadata.
3. Managed/Controlled Access: Sensitive, individual-level data that requires specific approval from a DAC. This is where the raw genomic sequences reside.

In a federated system, like the one described in CanDIG: Secure Federated Genomic Queries and Analyses Across Jurisdictions, these tiers are enforced automatically. A researcher might run a “discovery” query across five countries to find a cohort, but they can only “drill down” into the raw sequences once they’ve cleared the necessary regulatory hurdles at each site. This ensures that Federated Governance Complete Guide principles are upheld at every step, providing a clear audit trail for compliance officers.

Real-World Impact: From Pandemic Surveillance to Rare Disease Discovery

The power of Genomic data federation is best seen in crisis. During the COVID-19 pandemic, the Viral AI network processed 1.6 million SARS-CoV-2 genomes. Because the data stayed in its country of origin, national health agencies felt secure sharing their insights, leading to faster identification of new variants like Omicron. This real-time surveillance would have been impossible if every country had to wait for legal clearance to ship physical samples or upload raw data to a central server.

The European Genomic Data Infrastructure (GDI)

In the realm of population health, the European Genomic Data Infrastructure (GDI) project is currently working to realize the “1+ Million Genomes” initiative. By connecting national “nodes” across Europe, they are building a cross-border network that allows a doctor in Spain to compare a patient’s rare mutation with similar cases in Finland or Estonia. This is not just about research; it is about clinical decision support. When a clinician can find ten other patients globally with the same rare variant, they can better predict disease progression and choose the most effective treatment.

UK Biobank and Genomics England

We see similar success in the UK, where the UK Biobank enables the analysis of genetic data from 500,000 participants. By using a Lifebit Federated Trusted Research Environment Global Precision Medicine setup, researchers can run complex GWAS (Genome-Wide Association Studies) without the data ever leaving its secure environment. Similarly, Genomics England uses a federated approach to allow pharmaceutical partners to analyze the 100,000 Genomes Project data. This model protects the privacy of British citizens while providing the high-quality data needed for drug discovery. This is the blueprint for Federated Technology in Population Genomics.

Accelerating Drug Discovery

Pharmaceutical companies are also turning to federation to solve the “small n” problem in clinical trials. By federating data across multiple hospital systems, pharma researchers can identify eligible patients for trials much faster. Instead of spending years recruiting, they can query a federated network to find the exact genetic profiles they need in a matter of days. This reduces the cost of drug development and brings new therapies to market sooner.

Frequently Asked Questions about Federated Genomics

What is the difference between centralized and federated data sharing?

In centralized sharing, you copy data from various sources into one location. This creates a single point of failure and often violates data sovereignty laws. In Genomic data federation, the data stays with the original owner, and you send your analysis “questions” to the data instead. This is much safer for sensitive human data and significantly reduces the cost of data movement.

How does federation ensure compliance with GDPR and HIPAA?

Federation supports “data minimization”—a core principle of GDPR. Since the data never moves across borders, you don’t run into the legal “gray areas” of international data transfer. Each site maintains its own local security and compliance protocols, ensuring that Federated Learning in Healthcare remains fully legal. Furthermore, the audit logs in a federated system provide a transparent record of who accessed what data and for what purpose.

Can I run AI models on federated data without moving it?

Yes! This is exactly what AI for Federation is designed for. Through federated learning, you can train sophisticated machine learning models on decentralized datasets. The models get smarter by learning from the patterns in the data, but the raw patient data stays private. This is particularly useful for training diagnostic tools on rare disease data spread across multiple hospitals.

Is federation slower than centralized analysis?

While there is a slight overhead in coordinating queries across multiple sites, federation is often faster in practice. This is because you skip the months-long process of legal negotiations, data cleaning, and physical data transfer required for centralization. In a federated system, once the nodes are connected, analysis can happen in near real-time.

What are the technical requirements for joining a federated network?

To join a federated network, an institution typically needs a “federated node”—a secure server or cloud environment that can host the data and execute incoming queries. This node must be configured to support GA4GH standards like Beacon, WES, and Data Connect. Many organizations use platforms like Lifebit to simplify this deployment and ensure interoperability with global networks.

Conclusion: Scaling the Global Internet of Genomics

The era of the “data silo” is ending. We are moving toward a world where a researcher’s ability to cure a disease is no longer limited by the size of their local hard drive, but by the strength of their questions. The transition from centralized to federated models represents a fundamental shift in how we value and protect human biological information.

At Lifebit, we believe that Genomic data federation is the only sustainable way to scale precision medicine globally. By using a Lifebit Federated Biomedical Data Platform, institutions can join a secure, interoperable network that respects patient privacy while accelerating scientific breakthroughs. This approach democratizes access to data, allowing researchers from smaller institutions or developing nations to contribute to and benefit from global scientific progress.

Whether it’s identifying a new drug target in six hours or tracking a global pathogen in real-time, the future of medicine isn’t just about having the data—it’s about how we connect it. The infrastructure we build today will determine the speed of medical discovery for the next century. The future is federated, and it is happening now.

For more information on how to scale your research and join the global network of federated genomics, explore our Federated Data Platform Ultimate Guide.